---
title: "688068.SH (688068.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688068.SH/news.md"
symbol: "688068.SH"
name: "688068.SH"
parent: "https://longbridge.com/en/quote/688068.SH.md"
datetime: "2026-05-20T03:41:48.735Z"
locales:
  - [en](https://longbridge.com/en/quote/688068.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688068.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688068.SH/news.md)
---

# 688068.SH (688068.SH) — Related News

### [Hotgen: The Phase Ib clinical study of the AD treatment antibody drug AA001 is proceeding as scheduled](https://longbridge.com/en/news/286901708.md)
*2026-05-19T11:12:05.000Z*
> Hotgen released an announcement regarding unusual trading. The company's stock trading has experienced a cumulative decl

### [Hotgen: Investee company Aorui Biotechnology plans to receive an additional investment of 42 million yuan](https://longbridge.com/en/news/286540636.md)
*2026-05-15T09:40:47.000Z*
> Hotgen announced that Chuangjing Kangrun and Hangzhou Taimeng plan to increase their investment in the affiliated compan

### [Hotgen: Revenue of 405 million yuan in 2025, a year-on-year decrease of 20.58%, plans not to distribute dividends](https://longbridge.com/en/news/285899767.md)
*2026-05-11T07:40:29.000Z*
> Hotgen announced that the company's operating revenue for 2025 is expected to be 404.8753 million yuan, a year-on-year d

### [Hotgen's subsidiary ShunJing Pharmaceutical has obtained the "Specialized, Refined, Characteristic, and Innovative" small and medium-sized enterprise certificate from Beijing](https://longbridge.com/en/news/285560723.md)
*2026-05-07T13:20:58.000Z*
> Hotgen's subsidiary Beijing ShunJing Biomedical Technology Co., Ltd. recently received the "Specialized, Refined, Charac

### [Hotgen: Net loss of 68.0594 million yuan in the first quarter of 2026](https://longbridge.com/en/news/284008769.md)
*2026-04-24T13:08:32.000Z*
> Hotgen announced that its operating revenue in the first quarter of 2026 was 116 million yuan, a year-on-year increase o

### [Hotgen: Plans to acquire 42% equity in Yujing Pharmaceutical for 4.05 million yuan](https://longbridge.com/en/news/284008593.md)
*2026-04-24T13:07:40.000Z*
> Hotgen announced that it plans to acquire 42% equity in Beijing Yujing Pharmaceutical for 4.05 million yuan, and after t

### [Hotgen's subsidiary innovative drug SGT003 injection has obtained the Clinical Trial Application Acceptance Notice](https://longbridge.com/en/news/282326308.md)
*2026-04-10T10:12:05.000Z*
> Hotgen's subsidiary Beijing ShunJing Biomedical Technology Co., Ltd. recently received the "Acceptance Notification" fro

### [Hotgen: Has repurchased 904,100 shares, using a total of 150 million yuan](https://longbridge.com/en/news/281511772.md)
*2026-04-02T11:04:52.000Z*
> Hotgen announced that as of March 31, 2026, the company has repurchased a total of 904,054 shares through its dedicated